Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov
"... ). The estimated number of patients in Russia who need second-line treatment for CML is 996 patients. if nilotinib ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as firstline therapy ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... Federation – nilotinib (Tasigna) and imatinib (Gleevec) in CML in the chronic phase (CP) treatment as first ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
"... Abstract: lung cancer takes the second place in the general structure of incidence of malignant ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Pharmacoeconomic evaluation of treatment of the second and third lines of multiple myeloma ..."
 
Vol 11, No 4 (2018) Clinical and economic studies on pharmacotherapy of malignant neoplasms: the modeling approach Abstract  similar documents
A. G. Tolkushin, S. K. Zyryanov, N. L. Pogudina, M. V. Davydovskaya
"... before progression (first-line therapy), after progression (second-line therapy) and death. Considering ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... patients of the second (control group) received a course of conservatively treatment (analgetics, NSAIDs ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF THE THERAPY OF СHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS IN HOSPITAL CONDITIONS Abstract  similar documents
E. E. Vidyakina, S. V. Malchikova
"... the number of second line drugs is increased. Conclusion. Most of the financial costs were for the treatment ..."
 
Vol 7, No 4 (2014) АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS Abstract  similar documents
P. S. Nosova, O. V. Reshetko
"... to 2010 in both types of in-patient clinics. Consumption of second-generation antipsychotics increase ..."
 
Vol 9, No 3 (2016) CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov
"... . Scenario 1: in case of increase of total costs by 6.75%; 10.42% and 17.38% in the first, second and third ..."
 
Vol 9, No 2 (2016) PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA Abstract  similar documents
N. A. Avxentyev, M. Yu. Frolov
"... ,000 rubles less than second best option. The overall healthcare annual expenses of using combined drug are 5 ..."
 
Vol 7, No 3 (2014) PROBLEMS OF OUTCOMES CHOICE FOR THE ASSESSMENT OF REHABILITATION PROGRAMS EFFICIENCY IN PATIENTS AFTER STROKE AND CRANIOCEREBRAL INJURY Abstract  similar documents
V. S. Dombrovskiy, V. V. Omelyanovskiy
"... that proportion of patient without disability decreased by 4-fold between the first and second visits ..."
 
Vol 9, No 3 (2016) HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE Abstract  similar documents
A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina
"... compared 12 different treatment regimens of second, third and fourth therapy line in patients progressed ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... the pharmacoeconomic aspects of using enzalutamide, cabazitaxel and abiraterone for the second-line therapy of CRPC ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... ) immunization programme became cost-effective starting from the second year after vaccination and should ..."
 
Vol 7, No 2 (2014) EPIDEMIOLOGIC RESEARCH ON EPILEPSY IN MINSK Abstract  similar documents
T. V. Dokukina, T. S. Golubeva, I. V. Matveichuk, M. V. Mahrov, V. M. Loseva, E. V. Krupenkina, S. A. Marchuk
"... .0 % of subjects). The most commonly administered second-generation anti-epileptics were topiramate (7 ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... with subsequent second line therapy on the basis of non-nucleoside reverse transcriptase inhibitors (including ..."
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... of these two agents used with the second and subsequent lines of chemotherapy in common/metastatic STS ..."
 
Vol 10, No 1 (2017) BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS Abstract  similar documents
E. A. Pyadushkina
"... % and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... . ocrelizumab showed the efficacy similar to the second-line disease-modifying therapies, but it had a more ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... + alloSCT vs Ch ± RT per life year (LY) and quality-adjusted life year (QALY) was calculated. In the second ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... +* + – – – 4,76 – – 4,76 37 Блеомицин – + – – – 2,38 – 2,38 – 37 Ифосфамид – + – – – 2,38 – 2,38 – 37 Нилотиниб ..."
 
Vol 6, No 3 (2013) THE ANALYSIS OF THE MARKET OF PHARMACEUTICALS FOR DYSMENORRHEA TREATMENT Abstract  similar documents
N. Yu. Cherkasova, A. V. Fomina, O. V. Filippova
"... to menstruation, among first and second year female medical students/A. Singh, D. Kiran, H. Singh, B ..."
 
Vol 9, No 2 (2016) EPIDEMIOLOGICAL FEATURES OF NON-ALCOHOLIC FATTY LIVER DISEASE IN NOVOSIBIRSK (SIBERIAN FEDERAL DISTRICT): REGIONAL DATA OF OPEN MULTICENTER PROSPECTIVE STUDY DIREG 2 Abstract  similar documents
V. V. Tsukanov, A. S. Yurkina, T. A. Ushakova, D. V. Blinov
"... Fatty Liver Disease (NAFLD). GI Epidemiology: Diseases and Clinical Methodology, Second Edition. 2014 ..."
 
Vol 9, No 4 (2016) PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY) Abstract  similar documents
D. Kh. Kalimullina, A. S. Yurkina, T. I. Ushakova, D. V. Blinov
"... , Second Edition. 2014; 357-372. 20. Alberti K. G., Zimmet P., Shaw J.; IDF Epidemiology Task Force ..."
 
1 - 27 of 27 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)